Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is intended solely for the introduction of medications related to medical health and does not recommend treatment plans (if mentioned), nor does it represent the platform's position.Authorization is required for any article reprints.
Recently,Beijing Qinghui Liannuo Biotechnology Co., Ltd. (hereinafter referred to as “Qinghui Liannuo” or the “Company”) announced the completion of its Series A financing round, raising nearly RMB 200 million.This financing round was jointly participated in by Longpan Investment, Zhongguancun Capital, Beijing Pharmaceutical and Health Industry Investment Fund, Feitu Hongyuan, and Shenzhen Capital Group.The proceeds from the financing will be primarily used for clinical studies of the company’s core pipeline, proof-of-concept for early-stage innovative pipelines, and optimization of its technology platforms.
Qinghui Liannuo is an innovative biopharmaceutical company with γδ T cell immunotherapy technology as its core competency, founded under the leadership of Professor Zhang Yonghui from the School of Pharmaceutical Sciences at Tsinghua University. Professor Zhang is a Changjiang Scholar Distinguished Professor appointed by the Ministry of Education, a tenured professor at the School of Pharmaceutical Sciences of Tsinghua University, a researcher at the Tsinghua-Peking Center for Life Sciences, and a doctoral supervisor. He is also a Fellow of the Royal Society of Chemistry (FRSC) and serves as Associate Editor of RSC Medicinal Chemistry.As an innovative biopharmaceutical company focused on the development of γδ T cell immunotherapy, Qinghui LiannuoLeveraging a globally leading γδ T cell technology platform, we focus on addressing unmet clinical needs in oncology and autoimmune diseases, building a multi-dimensional R&D pipeline that includes allogeneic off-the-shelf cell therapy drugs and novel small-molecule agonists.Currently, three independently developed allogeneic γδ T-cell therapy products have entered clinical trials, demonstrating breakthrough efficacy in the treatment of glioma, B-cell malignancies, and acute myeloid leukemia.
The company’s independently developed QH104A, the world’s first “off-the-shelf” CAR-γδ T cell injection targeting B7-H3, has attracted significant attention.Last year, in the Phase I clinical study led by Professor Li Wenbin’s team at Beijing Tiantan Hospital, Capital Medical University, the product successfully completed dosing in the first patient with recurrent or progressive malignant central nervous system tumors.（World’s First! Qinghui Liannuo’s B7-H3 CAR-γδ T Product Completes First Dosing in Phase I Clinical Trial）Unlike traditional autologous CAR-T therapy, which requires weeks for individualized preparation, QH104A utilizes cells from healthy donors, enabling large-scale production and cryopreservation in advance. For clinical use, patients do not need to endure prolonged waiting periods; the product can be rapidly thawed and administered after quality re-verification. This "off-the-shelf" design effectively prevents treatment delays caused by extended manufacturing timelines for patients with rapidly progressing recurrent malignant brain tumors who have a very narrow therapeutic window, thereby enhancing the timeliness and accessibility of treatment.Furthermore, leveraging Qinghui Liannuo’s independently developed fully enclosed semi-automated production process system, QH104A has achieved large-scale manufacturing of cell therapies, significantly reducing the per-dose production cost of cell-based drugs.In addition to malignant central nervous system tumors, Qinghui Liannuo’s off-the-shelf γδ T-cell therapeutics for B-cell malignancies and autoimmune diseases have also demonstrated promising therapeutic potential and manageable safety profiles in investigator-initiated clinical studies. Leveraging the unique immune recognition mechanism of the γδ TCR/BTN axis, the company has further deployed innovative products with novel mechanisms of action across multiple hematologic and solid tumor indications where existing CAR-T therapies have shown suboptimal efficacy or faced significant challenges, thereby continuously enriching its pipeline portfolio.
The completion of this funding round provides financial support for Qinghui Liannuo’s next phase of R&D and clinical advancement. The company stated that it will continue to focus on the innovative field of γδ T cells, steadily advance the clinical translation and registration studies of its core pipeline, and promote the availability of domestically developed innovative cell therapies to benefit more patients.Reference: Qinghui Liannuo
Scan the QR code to join the groupMastering CAR-T Therapy, Stem Cell Therapy, and GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
